NASDAQ: SIONSionna Therapeutics Inc Stock
$11.30+0.23 (+2.08%)
Updated Apr 21, 2025
SION Price
$11.30
Fair Value Price
N/A
Market Cap
$498.61M
52 Week Low
$7.26
52 Week High
$25.19
P/E
-0.71x
P/B
-3.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$61.69M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.12
Operating Cash Flow
-$53M
Beta
0.6
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SION Overview
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SION's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SION
Ranked#143 of 462
Ranked#143 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important SION news, forecast changes, insider trades & much more!
SION News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SION scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SION is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SION is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
SION's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more SION due diligence checks available for Premium users.
Valuation
SION price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.71x
Industry
-184.27x
Market
27.14x
SION price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.05x
Industry
4.04x
SION's financial health
Profit margin
Revenue
$0.0
Net Income
-$15.8M
Profit Margin
0%
SION's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$185.8M
Liabilities
$19.1M
Debt to equity
-0.12
SION's short-term assets ($150.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SION's short-term assets ($150.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SION's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SION's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.8M
Investing
$15.2M
Financing
-$1.4M
SION's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SION vs Biotech Stocks
Sionna Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.